Global Search | Novartis

Hide Filters

Showing 2719 results

Press release / Sep 23, 2016

Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients

In a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
Press release / Sep 21, 2016

Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites…
Press release / Sep 23, 2016

Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions

Ilaris® (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA…
Press release / Sep 28, 2016

Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges

Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need Sandoz "HACk" - Healthcare Access Challenge - is…
Press release / Sep 28, 2016

Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine

ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo…
Press release / Oct 03, 2016

Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey

Global survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment[1]* Majority (84%) face…
Press release / Oct 01, 2016

Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

Cosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…
Press release / Oct 08, 2016

Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up

Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
Press release / Oct 08, 2016

Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…
Press release / Oct 09, 2016

Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study

Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…